Literature DB >> 23390442

Immune reconstitution after allogeneic hematopoietic stem cell transplantation in children: a single institution study of 59 patients.

Hyun O Kim1, Hyun Jin Oh, Jae Wook Lee, Pil-Sang Jang, Nack-Gyun Chung, Bin Cho, Hack-Ki Kim.   

Abstract

PURPOSE: Lymphocyte subset recovery is an important factor that determines the success of hematopoietic stem cell transplantation (HSCT). Temporal differences in the recovery of lymphocyte subsets and the factors influencing this recovery are important variables that affect a patient's post-transplant immune reconstitution, and therefore require investigation.
METHODS: The time taken to achieve lymphocyte subset recovery and the factors influencing this recovery were investigated in 59 children who had undergone HSCT at the Department of Pediatrics, The Catholic University of Korea Seoul St. Mary's Hospital, and who had an uneventful follow-up period of at least 1 year. Analyses were carried out at 3 and 12 months post-transplant. An additional study was performed 1 month post-transplant to evaluate natural killer (NK) cell recovery. The impact of pre- and post-transplant variables, including diagnosis of Epstein-Barr virus (EBV) DNAemia posttransplant, on lymphocyte recovery was evaluated.
RESULTS: THE LYMPHOCYTE SUBSETS RECOVERED IN THE FOLLOWING ORDER: NK cells, cytotoxic T cells, B cells, and helper T cells. At 1 month post-transplant, acute graft-versus-host disease was found to contribute significantly to the delay of CD16(+)/56(+) cell recovery. Younger patients showed delayed recovery of both CD3(+)/CD8(+) and CD19(+) cells. EBV DNAemia had a deleterious impact on the recovery of both CD3(+) and CD3(+)/CD4(+) lymphocytes at 1 year post-transplant.
CONCLUSION: In our pediatric allogeneic HSCT cohort, helper T cells were the last subset to recover. Younger age and EBV DNAemia had a negative impact on the post-transplant recovery of T cells and B cells.

Entities:  

Keywords:  Child; Hematopoietic stem cell transplantation; Immune reconstitution inflammatory syndrome; Lymphocyte subset

Year:  2013        PMID: 23390442      PMCID: PMC3564027          DOI: 10.3345/kjp.2013.56.1.26

Source DB:  PubMed          Journal:  Korean J Pediatr        ISSN: 1738-1061


  17 in total

1.  Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.

Authors:  Barbara C Gärtner; Hansjörg Schäfer; Katja Marggraff; Günter Eisele; Marco Schäfer; Dagmar Dilloo; Klaus Roemer; Hans-Jürgen Laws; Martina Sester; Urban Sester; Hermann Einsele; Nikolaus Mueller-Lantzsch
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

Review 2.  Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients.

Authors:  Daria Pagliara; Barbara Savoldo
Journal:  Curr Opin Infect Dis       Date:  2012-08       Impact factor: 4.915

3.  Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients.

Authors:  S J Stevens; E A Verschuuren; I Pronk; W van Der Bij; M C Harmsen; T H The; C J Meijer; A J van Den Brule; J M Middeldorp
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

4.  Reconstitution of lymphocyte subpopulations after paediatric bone marrow transplantation.

Authors:  E de Vries; M J van Tol; R L van den Bergh; J L Waaijer; M M ten Dam; J Hermans; J M Vossen
Journal:  Bone Marrow Transplant       Date:  2000-02       Impact factor: 5.483

5.  Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients.

Authors:  C Heining; A Spyridonidis; E Bernhardt; J Schulte-Mönting; D Behringer; C Grüllich; A Jakob; H Bertz; J Finke
Journal:  Bone Marrow Transplant       Date:  2007-03-26       Impact factor: 5.483

6.  Epstein-Barr virus-associated lymphoproliferative disorder developed following autologous peripheral blood stem cell transplantation for relapsing Hodgkin's lymphoma.

Authors:  Sakura Izumiya; Mitsuaki Ishida; Keiko Hodohara; Takashi Yoshida; Hidetoshi Okabe
Journal:  Oncol Lett       Date:  2012-04-03       Impact factor: 2.967

7.  The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation.

Authors:  H Olkinuora; E von Willebrand; J M Kantele; O Vainio; K Talvensaari; U Saarinen-Pihkala; S Siitonen; K Vettenranta
Journal:  Scand J Immunol       Date:  2011-06       Impact factor: 3.487

8.  Effect of in vivo lymphocyte-depleting strategies on development of lymphoproliferative disorders in children post allogeneic bone marrow transplantation.

Authors:  B A Lynch; M A Vasef; M Comito; A L Gilman; N Lee; J Ritchie; S Rumelhart; M Holida; F Goldman
Journal:  Bone Marrow Transplant       Date:  2003-09       Impact factor: 5.483

9.  Regulatory T cell activity in primary and persistent Epstein-Barr virus infection.

Authors:  P J Wingate; K A McAulay; I C Anthony; D H Crawford
Journal:  J Med Virol       Date:  2009-05       Impact factor: 2.327

10.  CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis.

Authors:  Michael P Pender
Journal:  Autoimmune Dis       Date:  2012-01-24
View more
  4 in total

1.  Immune reconstitution in patients with acquired severe aplastic anemia after haploidentical stem cell transplantation.

Authors:  X-Y Pei; X-Y Zhao; L-P Xu; Y Wang; X-H Zhang; Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2017-08-14       Impact factor: 5.483

2.  Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.

Authors:  Vissal David Kheav; Marc Busson; Catherine Scieux; Régis Peffault de Latour; Guitta Maki; Philippe Haas; Marie-Christine Mazeron; Maryvonnick Carmagnat; Emeline Masson; Aliénor Xhaard; Marie Robin; Patricia Ribaud; Nicolas Dulphy; Pascale Loiseau; Dominique Charron; Gérard Socié; Antoine Toubert; Hélène Moins-Teisserenc
Journal:  Haematologica       Date:  2014-08-01       Impact factor: 9.941

Review 3.  Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.

Authors:  Charlotte I S Barker; Eva Germovsek; Rollo L Hoare; Jodi M Lestner; Joanna Lewis; Joseph F Standing
Journal:  Adv Drug Deliv Rev       Date:  2014-01-17       Impact factor: 15.470

4.  Predicting CD4 T-Cell Reconstitution Following Pediatric Hematopoietic Stem Cell Transplantation.

Authors:  R L Hoare; P Veys; N Klein; R Callard; J F Standing
Journal:  Clin Pharmacol Ther       Date:  2017-05-26       Impact factor: 6.875

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.